Legend Biotech’s (LEGN) “Neutral” Rating Reiterated at JPMorgan Chase & Co.

Posted by George Bondi on Jul 13th, 2026

Legend Biotech (NASDAQ:LEGN – Get Free Report)‘s stock had its “neutral” rating reiterated by investment analysts at JPMorgan Chase & Co. in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $35.00 target price on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 29.25% from the company’s previous close.

Other equities research analysts have also issued reports about the company. UBS Group boosted their target price on Legend Biotech from $31.00 to $49.00 and gave the stock a “buy” rating in a research report on Wednesday, June 3rd. Weiss Ratings lowered Legend Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. HC Wainwright lifted their price target on Legend Biotech from $50.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, June 3rd. TD Cowen boosted their price objective on Legend Biotech to $29.00 and gave the stock a “hold” rating in a report on Wednesday, May 13th. Finally, Royal Bank Of Canada decreased their target price on shares of Legend Biotech from $64.00 to $63.00 and set an “outperform” rating for the company in a report on Tuesday, July 7th. Ten research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $57.00.

Get Our Latest Report on LEGN

Legend Biotech Stock Performance

Legend Biotech stock opened at $27.08 on Monday. The firm has a market cap of $5.03 billion, a price-to-earnings ratio of -39.82 and a beta of 0.34. Legend Biotech has a 1 year low of $16.24 and a 1 year high of $45.30. The firm’s 50 day moving average price is $29.69 and its two-hundred day moving average price is $23.29.

Legend Biotech (NASDAQ:LEGN – Get Free Report) last announced its quarterly earnings data on Wednesday, May 13th. The company reported ($0.03) EPS for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.01). The company had revenue of $305.10 million for the quarter, compared to analyst estimates of $306.51 million. Legend Biotech had a negative net margin of 21.98% and a negative return on equity of 24.92%. Legend Biotech’s revenue was up 56.5% on a year-over-year basis. During the same quarter last year, the company posted ($0.07) EPS. As a group, equities analysts predict that Legend Biotech will post -0.01 EPS for the current fiscal year.

Insider Transactions at Legend Biotech

In related news, CEO Ying Huang sold 5,566 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $14.78, for a total value of $82,265.48. Following the completion of the sale, the chief executive officer directly owned 241,872 shares of the company’s stock, valued at approximately $3,574,868.16. This represents a 2.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.02% of the company’s stock.

Hedge Funds Weigh In On Legend Biotech

A number of large investors have recently made changes to their positions in LEGN. SG Americas Securities LLC boosted its holdings in shares of Legend Biotech by 6,774.9% during the fourth quarter. SG Americas Securities LLC now owns 371,728 shares of the company’s stock worth $8,081,000 after purchasing an additional 366,321 shares during the period. Hudson Bay Capital Management LP increased its stake in Legend Biotech by 42.4% in the 3rd quarter. Hudson Bay Capital Management LP now owns 220,000 shares of the company’s stock valued at $7,174,000 after buying an additional 65,500 shares during the period. Y Intercept Hong Kong Ltd purchased a new stake in Legend Biotech in the 1st quarter worth approximately $4,039,000. Casdin Capital LLC purchased a new stake in Legend Biotech in the 4th quarter worth approximately $4,674,000. Finally, Eagle Health Investments LP acquired a new stake in shares of Legend Biotech during the 4th quarter valued at $8,884,000. Institutional investors and hedge funds own 70.89% of the company’s stock.

About Legend Biotech

(Get Free Report)

Legend Biotech (NASDAQ: LEGN) is a commercial-stage biopharmaceutical company specializing in the development and commercialization of chimeric antigen receptor T-cell (CAR-T) therapies for oncology. Headquartered in Somerset, New Jersey, with research and development operations in Shanghai, the company leverages a global infrastructure to advance innovative cellular therapies. Legend Biotech pursues a strategy of strategic collaboration to extend its reach, most notably through its partnership with Janssen Biotech, a subsidiary of Johnson & Johnson.

The company’s lead asset, ciltacabtagene autoleucel (commercially marketed as Carvykti), is a B-cell maturation antigen (BCMA)–directed CAR-T therapy for the treatment of relapsed or refractory multiple myeloma.